Novavax’s protein-based vaccine approval fails to boost stock as demand for shots and boosters remains low
U.S. health regulators authorized the use of Novavax Inc.’s COVID-19 vaccine, providing a new option…
Read MoreU.S. health regulators authorized the use of Novavax Inc.’s COVID-19 vaccine, providing a new option…
Read MoreA new, highly infectious subvariant of omicron is raising concerns among scientists and health experts…
Read MoreA new, highly infectious subvariant of omicron is raising concerns among scientists and health experts…
Read MoreWhile the daily average of new COVID-19 cases have settled back into a low-100K range…
Read MoreThe U.S. is gearing up for another wave of COVID-19 infections in the fall and…
Read MoreThe U.S. is gearing up for another wave of COVID-19 infections in the fall and…
Read MoreThe U.S. should pursue a COVID-19 booster strategy that focuses on developing new shots that…
Read More